Health Canada Licenses Qiagen's Hepatitis B Test
Posted on: Wednesday, 21 November 2007, 15:00 CST
Qiagen has announced that its newly released hepatitis B virus assay kit, known as artus HBV LC PCR Kit, is in compliance with Health Canada's medical device requirements.
The kit, which monitors the viral load of infected patients, is now available to doctors in Canada to help them determine the success of a treatment.
The ready-to-use molecular diagnostic detection kit for the quantitation of hepatitis B viral (HBV) DNA from plasma helps to monitor on-going drug therapy treatments for those people chronically infected with hepatitis B. The kit utilizes the polymerase chain reaction amplification technology and is configured for the widely available LightCycler Instrument.
The kit provides all necessary reagents optimized for reliable HBV DNA detection and quantitation, including of the HBV genotypes A to G. This spectrum of genotypes is representative of strains of the virus which can be found globally, ensuring highest sensitivity in monitoring of treatments, the company said.
Source: Datamonitor
Related Articles
- Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV By French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
- Pharmasset to Present at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9th
- Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
- R7128 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
- Pharmasset Commences Dosing in 28-Day Combination Study of R7128 With Pegasys(R) Plus Copegus(R) for Hepatitis C
- Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
- China OK's Worldwide's Hepatitis C Test
- Worldwide Biotech and Pharmaceutical Company Obtains Chinese FDA Regulation Approval for Its Product 'Diagnostic Kit to Hepatitis C Antibody (ELISA)'; the Only HCV Diagnostic Kit Developed From Intact HCV Virus on the Market
- Cubist Pharmaceuticals Announces the End of Patient Dosing in HepeX-B(TM) Hepatitis B Phase 2 Trial
- Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy*
 |
 |
User Comments (0)
RSS Feeds